PBK/TOPK: A Therapeutic Target Worthy of Attention
Open Access
- 11 February 2021
- Vol. 10 (2), 371
- https://doi.org/10.3390/cells10020371
Abstract
Accumulating evidence supports the role of PDZ-binding kinase (PBK)/T-lymphokine-activated killer-cell-originated protein kinase (TOPK) in mitosis and cell-cycle progression of mitotically active cells, especially proliferative malignant cells. PBK/TOPK was confirmed to be associated with the development, progression, and metastasis of malignancies. Therefore, it is a potential therapeutic target in cancer therapy. Many studies have been conducted to explore the clinical applicability of potent PBK/TOPK inhibitors. However, PBK/TOPK has also been shown to be overexpressed in normal proliferative cells, including sperm and neural precursor cells in the subventricular zone of the adult brain, as well as under pathological conditions, such as ischemic tissues, including the heart, brain, and kidney, and plays important roles in their physiological functions, including proliferation and self-renewal. Thus, more research is warranted to further our understanding of PBK/TOPK inhibitors before we can consider their applicability in clinical practice. In this study, we first review the findings, general features, and signaling mechanisms involved in the regulation of mitosis and cell cycle. We then review the functions of PBK/TOPK in pathological conditions, including tumors and ischemic conditions in the heart, brain, and kidney. Finally, we summarize the advances in potent and selective inhibitors and describe the potential use of PBK/TOPK inhibitors in clinical settings.Keywords
Funding Information
- the Natural Science Foundation in China (81801299, 81971222, 81771412, KM201910025019)
This publication has 76 references indexed in Scilit:
- PBK/TOPK expression in non‐small‐cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expressionHistopathology, 2013
- In silico structural and functional analysis of the human TOPK protein by structure modeling and molecular dynamics studiesJournal of Molecular Modeling, 2012
- T-LAK Cell-originated Protein Kinase (TOPK) Phosphorylation of MKP1 Protein Prevents Solar Ultraviolet Light-induced Inflammation through Inhibition of the p38 Protein Signaling PathwayJournal of Biological Chemistry, 2011
- Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPKCarcinogenesis: Integrative Cancer Research, 2011
- T-LAK Cell-originated Protein Kinase (TOPK) Phosphorylation of Prx1 at Ser-32 Prevents UVB-induced Apoptosis in RPMI7951 Melanoma Cells through the Regulation of Prx1 Peroxidase ActivityOnline Journal of Public Health Informatics, 2010
- PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21Oncogene, 2010
- Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patientsBritish Journal of Cancer, 2009
- Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein–protein interaction with tumor suppressor p53Biochemical and Biophysical Research Communications, 2007
- Lymphokine-Activated Killer T-Cell-Originated Protein Kinase Phosphorylation of Histone H2AX Prevents Arsenite-Induced Apoptosis in RPMI7951 Melanoma CellsClinical Cancer Research, 2006
- Characterization of a MAPKK-like protein kinase TOPKBiochemical and Biophysical Research Communications, 2004